4.7 Article

An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease

出版社

AMER THORACIC SOC
DOI: 10.1164/rccm.201501-0044ST

关键词

-

资金

  1. Bayer
  2. Chiesi
  3. Takeda
  4. Vifor Pharma
  5. Forest
  6. MedImmune
  7. Respironics
  8. Spectral Diagnostics
  9. GlaxoSmithKline
  10. AstraZeneca-MedImmune
  11. Boehringer Ingelheim
  12. Sunovion Pharmaceuticals
  13. Cardif Assistance
  14. Vaincre la Mucoviscidose
  15. Almirall
  16. AstraZeneca
  17. Vertex
  18. Spiration
  19. Pearl
  20. Gilead
  21. Merck Sharp Dohme
  22. Mundipharma
  23. PneumRx
  24. Medical Acoustics

向作者/读者索取更多资源

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this Official American Thoracic Society (ATS)/European Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management. Methods: Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarized, and then salient knowledge gaps were identified. Results: Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus. Conclusions: Great strides have been made in the diagnosis, assessment, and management of COPD as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ERS Research Statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centered Outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据